404 related articles for article (PubMed ID: 24589925)
1. Efficacy of intermittent combined RAF and MEK inhibition in a patient with concurrent BRAF- and NRAS-mutant malignancies.
Abdel-Wahab O; Klimek VM; Gaskell AA; Viale A; Cheng D; Kim E; Rampal R; Bluth M; Harding JJ; Callahan MK; Merghoub T; Berger MF; Solit DB; Rosen N; Levine RL; Chapman PB
Cancer Discov; 2014 May; 4(5):538-45. PubMed ID: 24589925
[TBL] [Abstract][Full Text] [Related]
2. Combination of vemurafenib and cobimetinib in patients with advanced BRAF(V600)-mutated melanoma: a phase 1b study.
Ribas A; Gonzalez R; Pavlick A; Hamid O; Gajewski TF; Daud A; Flaherty L; Logan T; Chmielowski B; Lewis K; Kee D; Boasberg P; Yin M; Chan I; Musib L; Choong N; Puzanov I; McArthur GA
Lancet Oncol; 2014 Aug; 15(9):954-65. PubMed ID: 25037139
[TBL] [Abstract][Full Text] [Related]
3. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma.
Larkin J; Ascierto PA; Dréno B; Atkinson V; Liszkay G; Maio M; Mandalà M; Demidov L; Stroyakovskiy D; Thomas L; de la Cruz-Merino L; Dutriaux C; Garbe C; Sovak MA; Chang I; Choong N; Hack SP; McArthur GA; Ribas A
N Engl J Med; 2014 Nov; 371(20):1867-76. PubMed ID: 25265494
[TBL] [Abstract][Full Text] [Related]
4. Cobimetinib.
Signorelli J; Shah Gandhi A
Ann Pharmacother; 2017 Feb; 51(2):146-153. PubMed ID: 27701080
[TBL] [Abstract][Full Text] [Related]
5. Cobimetinib Plus Vemurafenib: A Review in BRAF (V600) Mutation-Positive Unresectable or Metastatic Melanoma.
Keating GM
Drugs; 2016 Apr; 76(5):605-15. PubMed ID: 26984388
[TBL] [Abstract][Full Text] [Related]
6. Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial.
Ascierto PA; McArthur GA; Dréno B; Atkinson V; Liszkay G; Di Giacomo AM; Mandalà M; Demidov L; Stroyakovskiy D; Thomas L; de la Cruz-Merino L; Dutriaux C; Garbe C; Yan Y; Wongchenko M; Chang I; Hsu JJ; Koralek DO; Rooney I; Ribas A; Larkin J
Lancet Oncol; 2016 Sep; 17(9):1248-60. PubMed ID: 27480103
[TBL] [Abstract][Full Text] [Related]
7. Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma.
Trunzer K; Pavlick AC; Schuchter L; Gonzalez R; McArthur GA; Hutson TE; Moschos SJ; Flaherty KT; Kim KB; Weber JS; Hersey P; Long GV; Lawrence D; Ott PA; Amaravadi RK; Lewis KD; Puzanov I; Lo RS; Koehler A; Kockx M; Spleiss O; Schell-Steven A; Gilbert HN; Cockey L; Bollag G; Lee RJ; Joe AK; Sosman JA; Ribas A
J Clin Oncol; 2013 May; 31(14):1767-74. PubMed ID: 23569304
[TBL] [Abstract][Full Text] [Related]
8. BRAF inhibitor-associated ERK activation drives development of chronic lymphocytic leukemia.
Yaktapour N; Meiss F; Mastroianni J; Zenz T; Andrlova H; Mathew NR; Claus R; Hutter B; Fröhling S; Brors B; Pfeifer D; Pantic M; Bartsch I; Spehl TS; Meyer PT; Duyster J; Zirlik K; Brummer T; Zeiser R
J Clin Invest; 2014 Nov; 124(11):5074-84. PubMed ID: 25329694
[TBL] [Abstract][Full Text] [Related]
9. Molecular pathways: adaptive kinome reprogramming in response to targeted inhibition of the BRAF-MEK-ERK pathway in cancer.
Johnson GL; Stuhlmiller TJ; Angus SP; Zawistowski JS; Graves LM
Clin Cancer Res; 2014 May; 20(10):2516-22. PubMed ID: 24664307
[TBL] [Abstract][Full Text] [Related]
10. Mitogen-activated protein kinase (MAPK) hyperactivation and enhanced NRAS expression drive acquired vemurafenib resistance in V600E BRAF melanoma cells.
Lidsky M; Antoun G; Speicher P; Adams B; Turley R; Augustine C; Tyler D; Ali-Osman F
J Biol Chem; 2014 Oct; 289(40):27714-26. PubMed ID: 25063807
[TBL] [Abstract][Full Text] [Related]
11. Identification of NRAS isoform 2 overexpression as a mechanism facilitating BRAF inhibitor resistance in malignant melanoma.
Duggan MC; Stiff AR; Bainazar M; Regan K; Olaverria Salavaggione GN; Maharry S; Blachly JS; Krischak M; Walker CJ; Latchana N; Tridandapani S; de la Chapelle A; Eisfeld AK; Carson WE
Proc Natl Acad Sci U S A; 2017 Sep; 114(36):9629-9634. PubMed ID: 28827320
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of mutant BRAF splice variant signaling by next-generation, selective RAF inhibitors.
Basile KJ; Le K; Hartsough EJ; Aplin AE
Pigment Cell Melanoma Res; 2014 May; 27(3):479-84. PubMed ID: 24422853
[TBL] [Abstract][Full Text] [Related]
13. Vemurafenib in combination with cobimetinib in relapsed and refractory extramedullary multiple myeloma harboring the BRAF V600E mutation.
Mey UJM; Renner C; von Moos R
Hematol Oncol; 2017 Dec; 35(4):890-893. PubMed ID: 27641727
[TBL] [Abstract][Full Text] [Related]
14. Cobimetinib and vemurafenib for the treatment of melanoma.
Boespflug A; Thomas L
Expert Opin Pharmacother; 2016; 17(7):1005-11. PubMed ID: 26999478
[TBL] [Abstract][Full Text] [Related]
15. Progression of RAS-mutant leukemia during RAF inhibitor treatment.
Callahan MK; Rampal R; Harding JJ; Klimek VM; Chung YR; Merghoub T; Wolchok JD; Solit DB; Rosen N; Abdel-Wahab O; Levine RL; Chapman PB
N Engl J Med; 2012 Dec; 367(24):2316-21. PubMed ID: 23134356
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of MERTK Promotes Suppression of Tumor Growth in BRAF Mutant and BRAF Wild-Type Melanoma.
Sinik L; Minson KA; Tentler JJ; Carrico J; Bagby SM; Robinson WA; Kami R; Burstyn-Cohen T; Eckhardt SG; Wang X; Frye SV; Earp HS; DeRyckere D; Graham DK
Mol Cancer Ther; 2019 Feb; 18(2):278-288. PubMed ID: 30482852
[TBL] [Abstract][Full Text] [Related]
17. Resistance to selective BRAF inhibition can be mediated by modest upstream pathway activation.
Su F; Bradley WD; Wang Q; Yang H; Xu L; Higgins B; Kolinsky K; Packman K; Kim MJ; Trunzer K; Lee RJ; Schostack K; Carter J; Albert T; Germer S; Rosinski J; Martin M; Simcox ME; Lestini B; Heimbrook D; Bollag G
Cancer Res; 2012 Feb; 72(4):969-78. PubMed ID: 22205714
[TBL] [Abstract][Full Text] [Related]
18. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma.
Bollag G; Hirth P; Tsai J; Zhang J; Ibrahim PN; Cho H; Spevak W; Zhang C; Zhang Y; Habets G; Burton EA; Wong B; Tsang G; West BL; Powell B; Shellooe R; Marimuthu A; Nguyen H; Zhang KY; Artis DR; Schlessinger J; Su F; Higgins B; Iyer R; D'Andrea K; Koehler A; Stumm M; Lin PS; Lee RJ; Grippo J; Puzanov I; Kim KB; Ribas A; McArthur GA; Sosman JA; Chapman PB; Flaherty KT; Xu X; Nathanson KL; Nolop K
Nature; 2010 Sep; 467(7315):596-9. PubMed ID: 20823850
[TBL] [Abstract][Full Text] [Related]
19. Antitumor activity of the ERK inhibitor SCH772984 [corrected] against BRAF mutant, NRAS mutant and wild-type melanoma.
Wong DJ; Robert L; Atefi MS; Lassen A; Avarappatt G; Cerniglia M; Avramis E; Tsoi J; Foulad D; Graeber TG; Comin-Anduix B; Samatar A; Lo RS; Ribas A
Mol Cancer; 2014 Aug; 13():194. PubMed ID: 25142146
[TBL] [Abstract][Full Text] [Related]
20. Incidence, course, and management of toxicities associated with cobimetinib in combination with vemurafenib in the coBRIM study.
Dréno B; Ribas A; Larkin J; Ascierto PA; Hauschild A; Thomas L; Grob JJ; Koralek DO; Rooney I; Hsu JJ; McKenna EF; McArthur GA
Ann Oncol; 2017 May; 28(5):1137-1144. PubMed ID: 28444112
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
